Home » Products » Immunoassays » 27784 GLP-1, Active form Assay Kit
- 27784
- GLP-1, Active form Assay Kit
| Format | ELISA/EIA |
|---|---|
| Storage | 2 - 8℃ |
| Package | 96 wells |
| Species | Human/Mouse/Rat |
| Sample types | EDTA Plasma/Culture media |
| Sample size | 100uL |
| Sensitivity | 0.10 pmol/L |
| Range | 1.25 - 80 pmol/L (4.1 - 263.8 pg/mL of GLP-1 (7-36) amide (as molecular weight is 3297.6)) |
| Protocol | 1st incubation 60 min, 2nd incubation 60 min, 3rd incubation 30min. |
| Download (protocol) | protocol |
| Download (MSDS) | msds |
| Note | Detection Target name Active GLP-1
Description Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating. They also inhibit glucagon release from the alpha cells of the islets of Langerhans. As a result, they slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and Gastric inhibitory peptide (or glucose-dependent insulinotropic polypeptide or GIP). The human proglucagon gene was cloned in 1983, and the human proglucagon sequence was subsequently deduced. After that, it was found that the specific sequence of GLP-1 has insulinotropic effect: GLP-1 (7-36) amide. Now, GLP-1 (7-36) amide and GLP-1 (7-37) are known as active forms of GLP-1. They are rapidly inactivated to GLP-1 (9-36) amide and GLP-1 (9-37) by DPP-IV within a few moments in blood. Currently, Several DPP-IV inhibitors that can be taken orally as a tablet have already been developed as a treatment for diabetes. This ELISA kit can measure Active forms of GLP-1 (GLP-1 (7-36) amide and GLP-1 (7-37)) specifically.
This product is useful for Diabetes / Obesity study.
※This product is available only in USA and Canada. |
